| scholarly article | Q13442814 |
| P50 | author | Masaki Shiota | Q60390038 |
| Ario Takeuchi | Q123738398 | ||
| P2093 | author name string | Katsunori Tatsugami | |
| Kenjiro Imada | |||
| Seiji Naito | |||
| Takeshi Uchiumi | |||
| Akira Yokomizo | |||
| Eiji Kashiwagi | |||
| Junichi Inokuchi | |||
| Momoe Itsumi | |||
| P2860 | cites work | Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor | Q39138335 |
| Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers | Q39335656 | ||
| Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer | Q39345959 | ||
| MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition | Q39411394 | ||
| Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer | Q39460386 | ||
| Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells | Q39630735 | ||
| Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer. | Q39683668 | ||
| Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. | Q39786200 | ||
| Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth | Q39868606 | ||
| The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling | Q40364004 | ||
| Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. | Q50744999 | ||
| Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. | Q50848979 | ||
| Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase | Q64378324 | ||
| Rsk1 mediates a MEK-MAP kinase cell survival signal | Q22253213 | ||
| C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival | Q24291845 | ||
| The RSK family of kinases: emerging roles in cellular signalling | Q24315679 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer | Q26852582 | ||
| Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms | Q28137802 | ||
| Nuclear translocation of the Y-box binding protein by ultraviolet irradiation | Q28257567 | ||
| Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase | Q28283499 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| RSK in tumorigenesis: connections to steroid signaling | Q30433106 | ||
| Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation | Q30437044 | ||
| Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter | Q33292543 | ||
| Targeting RSK: an overview of small molecule inhibitors | Q33376012 | ||
| Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance | Q33766973 | ||
| Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells | Q33775667 | ||
| Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity | Q33810134 | ||
| Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability | Q34117426 | ||
| Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation | Q34359234 | ||
| The pleiotropic functions of the Y-box-binding protein, YB-1. | Q35158110 | ||
| Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation | Q35558949 | ||
| An update on androgen deprivation therapy for prostate cancer | Q36289952 | ||
| Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells | Q37131331 | ||
| Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. | Q37837732 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Regulation and function of the RSK family of protein kinases | Q37970380 | ||
| Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration. | Q38091759 | ||
| YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity | Q38343224 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 829-838 | |
| P577 | publication date | 2014-04-12 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer | |
| P478 | volume | 74 |
| Q38778712 | A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line |
| Q58697074 | Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants |
| Q38924997 | Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity |
| Q42288454 | GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. |
| Q35038605 | High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer |
| Q36299754 | Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells |
| Q64246203 | KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer |
| Q47678215 | Polypharmacology-based ceritinib repurposing using integrated functional proteomics |
| Q38795167 | Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine |
| Q92619546 | TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer |
Search more.